An evaluation of the sensitivity of the Ames assay to discern low-level mutagenic impurities

Regulatory Toxicology and Pharmacology

Volumn 48, Issue 1, 2007, Pages 75-86

  Kenyon, Michelle O ^a   Cheung, Jennifer R ^a   Dobo, Krista L ^a   Ku, Warren W ^a  

^a PFIZER INC   (United States)

Author keywords

Carcinogen; Genetic safety; Genotoxic impurity; Genotoxicity; Mutagen; Structural alerts; Structure activity relationship (SAR); Synthetic intermediate

Indexed keywords

AMES TEST; ARTICLE; DATA BASE; DRUG IMPURITY; EVALUATION; GENOTOXICITY; MUTAGEN TESTING; MUTAGENICITY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STRUCTURE ANALYSIS;

BACTERIOLOGICAL TECHNIQUES; DATA COLLECTION; DRUG CONTAMINATION; MUTAGENICITY TESTS; MUTAGENS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; SENSITIVITY AND SPECIFICITY;

EID: 34249088320     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2007.01.006     Document Type: Article

References (71)

1. Ackerman, J., Hayashi, T., Hitchcock, J., Li, L., Lu, S., Nagai, Y., Spence, F., Aubrecht, J. 2005. Inter-laboratory evaluation of the bioluminescent Salmonella reverse mutation assay using 10 model chemicals. In: 9th International Conference on Environmental Mutagens and 36th Annual Meeting of the Environmental Mutagenesis Society Abstracts, San Francisco, CA.
2. Ashby J., Paton D., and Callander R.D. Potent mutagenicity to Salmonella of an equimolar mixture of 52 chemicals used in five collaborative studies. Mutagenesis 3 4 (1988) 245-247
3. Aubrecht, J., Osowski, J., Ku, W., Persaud, P., Cheung, J., Ackerman, J., Hoogedoorn, S., Blake, J., 2003. Bioluminescent Salmonella Reverse Mutation Assay: A High Throughput Screen For Detecting Mutagenicity. In: 2003 EMS Annual Meeting Poster Session, Miami Beach, Florida.
4. Barbarash R.A., Baumann J.L., Fischer J.H., Kondos G.T., and Batenhorst R.L. Near total reduction in verapamil bioavailability by rifampicine. Chest 94 (1988) 954-959
5. Berridge J.C. Impurities in drug substances and drug products: new approaches to quantification and qualification. J. Pharm. Biomed. Anal. 14 (1995) 7-12
6. Boehlert J.P. Impurities-Where are we now?. Pharm. Technol. 21 (1997) 56-60
7. Burke D.A., Wed D.J., and Burlison B. Use of the miniscreen assay to screen novel compounds for bacterial mutagenicity in the pharmaceutical industry. Mutagenesis 11 2 (1996) 201-205
8. Butterfield A.G., Curran N.M., Lovering E.G., Matsui F.F., Robertson D.L., and Sears R.W. Determination of hydrazine in pharmaceuticals I. Isoniazid. Can. J. Pharm. Sci. 16 1 (1981) 15-19
9. Cartwright A.C. Toxicology of impurities in organic synthetic drugs. Int. Pharm. J. 4 (1990) 146-150
10. Cashman J.R. Enantioselective N-oxygenation of verapamil by hepatic flavin-containing monooxygenase. Mol. Pharmacol. 36 (1989) 497-503
11. Cheung, J.R., Osowski, J.J., Aubrecht, J., 2005. Bioluminescent Reverse Mutation Assay Validation Using E. coli (WP2 uvrA pKM101) and Salmonella strains TA1535 and TA1537. In: 9th International Conference on Environmental Mutagens and 36th Annual Meeting of the Environmental Mutagenesis Society Abstracts, San Francisco, CA.
12. Clark J.K., and Barker H.G. Is mannitol metabolized?. Proc. Soc. Exp. Biol. Med. 69 (1948) 152-153
13. De Flora S., Camoirano A., Cartiglia C., and Ferguson L. Modulation of the potency of promutagens and direct acting mutagens in bacteria by inhibitors of the multidrug resistance mechanism. Mutagenesis 12 6 (1997) 431-435
14. Diehl M., and Fort F. Spiral Salmonella assay: validation against the standard pour-plate assay. Environ. Mol. Mutagen. 27 3 (1996) 227-236
15. Diehl M.S., Willaby S.L., and Snyder R.D. Comparison of the results of a modified miniscreen and the standard bacterial reverse mutation assays. Environ. Mol. Mutagen. 36 1 (2000) 72-77
16. Dobias L., Kusova J., Gajdos O., Vidova P., Gajdosova D., Havrankove J., Fried M., Binkove B., and Topinka J. Bioassay-directed chemical analysis and detection of mutagenicity in ambient air of the coke oven. Mut. Res. 445 2 (1999) 285-293
17. Dobo K.L., Greene N., Cyr M.O., Caron S., and Ku W.W. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development. Regul. Toxicol. Pharm. 44 3 (2006) 282-293
18. Dunn J.J., Lee L.S., and Ciegler A. Mutagenicity and toxicity of aflatoxin precursors. Mutagenesis 4 (1982) 19-26
19. Echhardt K., King M.T., Gocke E., and Wild D. Mutagenicity study of Remsen-Fahlberg saccharin and contaminants. Toxicol. Lett. 7 (1980) 51-60
20. European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use, June 2006. Guideline on the Limits of Genotoxic Impurities. http://www.emea.europa.eu/pdfs/human/swp/519902en.pdf.
21. Erni F., and Helboe P. ICH guideline on impurities in new drug products. Pharm. Technol. Intern. 8 (1996) 28-30
22. Flamand N., Meunier J.-R., Meunier P.-A., and Agapakis-Causse C. Mini mutagenicity test: a miniaturized version of the Ames test used in a prescreening assay for point mutagenesis assessment. Toxicol in Vitro 15 2 (2001) 105-114
23. Forrester L.M., Neal G.E., Judah D.J., Glancey M.J., and Wolf C.R. Evidence of involvement of multiple forms of cytochrome P-450 in aflatoxin b1 metabolism in human liver. Proc. Natl. Acad. Sci. USA 87 (1990) 8306-8310
24. Friscia O., Pulci R., Fassio F., and Comelli R. Chemical reagents as potential impurities of pharmaceutical products: investigations on their genotoxic activity. J. Environ. Pathol. Toxicol. Oncol. 13 (1994) 89-110
25. Gold L.S., and Zeiger E. Handbook of Carcinogenic Potency and Genotoxicity Databases (1997), CRC Press, Boca Raton, FL
26. Greene N., Judson P.N., Langowski J.J., and Marchant C.A. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR & QSAR Environ. Res. 10 2-3 (1999) 299-314
27. Guerin M.R., Clark B.R., Ho C.H., Epler J.L., and Rao T.K. Short-term bioassay of complex organic mixtures: Part I. Chemistry. Environ. Sci. Res. 15 (1979) 247-268 (Appl. Short-term Bioassays Fractionation Anal. Complex Environ. Mixtures)
28. Hakura A., Suzuki S., and Satoh T. Advantage of the use of human liver S9 in the Ames test. Mutat. Res. 438 (1999) 29-36
29. Hakura A., Suzuki S., Sawada S., Sugihara T., Hori Y., Uchida K., Kerns W.D., Sagami F., Motooka S., and Satoh T. Use of human liver S9 in the Ames test: assay of three procarcinogens using human S9 derived from multiple donors. Regul. Toxicol. Pharm. 37 (2003) 20-27
30. Haworth S., Lawlor T., Mortelmans K., Speck W., and Zeiger E. Salmonella mutagenicity test results for 250 chemicals. Environ. Mutagen. 5 Suppl. 1 (1983) 3-142
31. Hoyer M.E., Keeler G.J., and Ball J.C. Detection of oxidative mutagens in an urban air-particulate extract: a preliminary study. Mut. Res. 283 4 (1992) 295-299
32. ICH Harmonized Tripartite Guideline S2A: Guidance on Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals. July 1995. http://www.ich.org/.
33. ICH Harmonized Tripartite Guideline Q3C: Guideline for Residual Solvents. July 1997. http://www.ich.org/.
34. ICH Harmonized Tripartite Guideline Q3A(R): Impurities in New Drug Substances. February 2002. http://www.ich.org/.
35. ICH Harmonized Tripartite Guideline Q3B(R): Impurities in New Drug Products. February 2003 http://www.ich.org/.
36. Jones D.R., Gorski J.C., Hamman M.A., Mayhew B.S., Rider S., and Hall S.D. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J. Pharacol. Exp. Ther. 290 (1999) 1116-1125
37. Judson P.N., Cooke P.A., Doerrer N.G., Greene N., Hanzlik R.P., Hardy C., Hartmann A., Hinchliffe D., Holder J., Müller L., Steger-Hartmann T., Rothfuss A., Smith M., Thomas K., Vessey J.D., and Zeiger E. Towards the creation of an international toxicology information centre. Toxicology 213 (2005) 117-128
38. Kier L.E., Bursick D.J., Auletta A.E., Von Halle E.S., Brown M.M., Simmon V.F., Dunkel V., McCann J., Mortelmans K., Prival M., Rao T.K., and Ray V. The Salmonella typhimurium/mammalian microsomal assay: a report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat. Res. 168 (1986) 69-240
39. Kroemer H.K., Gautier J.-C., Beaune P., Henderson C., Wolf C.R., and Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn-Schmiedeberg's Arch. Pharmacol. 348 (1993) 332-337
40. Kropko M.L., Jaen J.C., Theiss J.C., Wold S., Caprathe B.W., and Wise L.D. Chemical purity and mutagenicity: case study of a drug in development. Mutat. Res. 281 4 (1992) 233-238
41. Kubo T., Urano K., and Utsumi H. Mutagenicity characteristics of 255 environmental chemicals. J. Health Sci. 48 6 (2002) 545-554
42. Lohman P.H.M. Qualitative and quantitative procedures for health risk assessment. Mutat. Res. 428 (1999) 237-254
43. Lohman P.H.M., Mendelsohn M.L., Moore II D.H., Waters M.D., Brusick D.J., Ashby J., and Lohman W.J. International commission for protection against environmental mutagens and carcinogens. A method for comparing and combining short-term genotoxicity test data: the basic system. Mutat. Res. 266 1 (1992) 7-25
44. Maeki-Paakkanen J., Komulainen H., and Kronberg L. Bacterial and mammalian-cell genotoxicity of mixtures of chlorohydroxyfuranones, by-products of water chlorination. Environ. Mol. Mutagen. 43 4 (2004) 217-225
45. Mäenpää J., Ruskoaho H., and Pelkonen O. Inhibition of hepatic microsomal drug metabolites in rats by five calcium channel antagonists. Pharmacol. Toxicol. 64 (1989) 446-450
46. Mahoney K., Scales M.D.C., and Tucker M.L. Impurities in organic synthetic drugs: a review of regulatory and toxicological considerations. Adverse Drug React. Toxicol. Rev. 12 (1993) 129-138
47. Maron D.M., and Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113 (1983) 173-215
48. Matsui F., Butterfield A.G., Curran N.M., Lovering E.G., Sears R.W., and Robertson D.L. Determination of hydrazine in pharmaceuticals II. Phenelzine sulfate. Can. J. Pharm. Sci. 16 (1981) 20-22
49. Matsui F., Robertson D.S., and Lovering E.G. Determination of hydrazine in pharmaceuticals III: hydralazine and isoniazid using GLC. J. Pharm. Sci. 72 (1983) 948-951
50. McCann J., Choi E., Yamasaki E., and Ames B.N. Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. Proc. Nat. Acad. Sci. USA 2 12 (1975) 5135-5137
51. McGinnity D.F., Parker A.J., Soars M., and Riley R.J. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metab. Disp. 28 (2000) 1327-1334
52. Moller H., and Donaubauer H.H. Qualification of specification for impurities in new drug substances. Eur. J. Pharm. Biopharm. 40 (1994) 53-57
53. Mortelmans K., Haworth S., Lawlor T., Speck W., Tainer B., and Zeiger E. Salmonella mutagenicity tests: II. Results from the testing of 270 chemicals. Environ. Mutagen. 8 Suppl. 7 (1986) 1-119
54. Müller L., Mauthe R.J., Riley C.M., Andino M.M., DeAntonis D., Beels C., DeGeorge J., DeKnaep A.G.M., Ellison D., Fagerland J.A., Frank R., Fritschel B., Harpur E., Humfrey C.D.N., Jagota N., Macinnon J., Mohan G., Ness D.K., O'Donovan M.R., Smith M.D., Vudathala G., and Yotti L. A rationale for determining, testing and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. Toxicol. Pharm. 44 3 (2006) 198-211
55. OECD Guideline for Testing of Chemicals, July 1997. "Genetic Toxicology: Bacterial Reverse Mutation Test" Section 471:1-11.
56. Otero Lobato M., Jenneskens L., and Seinen W. Bacterial mutagenicity of dicyclopenta-fused pyrene congeners in FVT pyrolysates: partial combustion exhaust mimics. Polycycl. Aromat. Comp. 24 4-5 (2004) 567-582
57. Page C.P., Curtis M.J., Sutter M.C., Walker M.J.A., and Hoffman B.B. Factors influencing the action of drugs: drug metabolism. Integrated Pharmacology (1997), Mosby, Barcelona, Spain 72-76
58. Pichard L., Gillet G., Fabre I., Dalet-Beluche I., Bonfils C., Thenot J.-P., and Maurel P. Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Met. Disp. 18 5 (1990) 711-719
59. Ridings J.E., Barratt M.D., Cary R., Earnshaw C.G., Eggington E.E., Ellis M.K., Judson P.N., Langowski J.J., Marchant C.A., Payne M.P., Watson W.P., and Yih T.D. Computer prediction of possible toxic action from chemical structure: an update on the DEREK system. Toxicology 106 (1996) 267-279
60. Riggin R.M., Margard W.L., and Kinzer G.W. Characterization of impurities in commercial lots of sodium saccharin produced by the Sherwin-Williams process II. Mutagen. Food Chem. Toxicol. 21 (1983) 11-17
61. Sanderson D.M., and Earnshaw C.G. Computer prediction of possible toxic action from chemical structure: the DEREK system. Hum. Exp. Toxicol. 10 (1991) 261-273
62. Shimada T., Nakamura S.-I., Imaoka S., and Funae Y. Genotoxic and mutagenic activation of aflatoxin b1 by constitutive forms of cytochrome P-450 in rat liver microsomes. Toxicol. Appl. Pharmacol. 91 (1987) 13-21
63. Shimizu R.W., Benson J.M., Li A.P., Henderson R.F., and Brooks A.L. Evaluation of the genotoxicity of process stream extracts from a coal gasification system. Environ. Mutagen. 6 6 (1984) 825-834
64. Sutton D., Butler A.M., Nadlin L., and Murray M. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J. Pharmacol. Exp. Ther. 28 (1997) 294-300
65. Todd W.R., Myers J., and West E.S. The metabolism of sorbitol and mannitol. J. Biol. Chem. 127 (1939) 275-284
66. Uchida E., Takahashi N., Kobayashi S., Kai K., Iida S., Kurato T., Hamada K., and Yasuhara H. The effect of diltiazem and verapamil on hepatic microsomal drug metabolizing enzymes in rat. Showa Univ. J. Med. Sci. 3 1 (1991) 24-27
67. Waters M.D., Stack H.F., Garrett N.E., and Jackson M.A. The genetic activity profile database. Environ. Health Perspect. 96 (1991) 41-45
68. Wheeler L., Halula M., and Demeo M. A comparison of aflatoxin b1-induced cytotoxicity, mutagenicity and prophage induction in Salmonella typhimurium mutagen tester strains TA1535, TA1538, TA98 and TA100. Mutat. Res. 83 (1981) 39-48
69. Zeiger E., Anderson B., Haworth S., Lawlor T., Mortelmans K., and Speck W. Salmonella mutagenicity tests: III. Results from the testing of 255 chemicals. Environ. Mutagen. 9 Suppl. 9 (1987) 1-109
70. Zeiger E., Anderson B., Haworth S., Lawlor T., and Mortelmans K. Salmonella mutagenicity tests: IV. Results from the testing of 300 chemicals. Environ. Mol. Mutagen. 11 Suppl. 12 (1988) 1-157
71. Zeiger E., Anderson B., Haworth S., Lawlor T., and Mortelmans K. Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals. Environ. Mol. Mutagen. 19 Suppl. 21 (1992) 2-141